MIT Jameel Clinic
The MIT Abdul Latif Jameel Clinic for Machine Learning in Health (commonly, MIT Jameel Clinic; previously, J-Clinic) is a research center at the Massachusetts Institute of Technology (MIT) in the field of artificial intelligence (AI) and health sciences, including disease detection, drug discovery, and the development of medical devices. The MIT Jameel Clinic also supports the commercialization of solutions through grant funding, and has partnered with pharmaceutical companies, like Takeda and Sanofi, and philanthropies, like Community Jameel and Wellcome Trust, to forge collaborations between research and development functions and MIT researchers.
| Established | 2018 |
|---|---|
Field of research | Artificial intelligence and health |
| Directors | Regina Barzilay James J. Collins Dimitris Bertsimas |
Chairs | Dan Huttenlocher Phil Sharp |
| Campus | Massachusetts Institute of Technology |
| Affiliations | MIT Schwarzman College of Computing |
| Phil Sharp | |
| Website | jclinic |
Co-founded in 2018 by MIT and Community Jameel, the MIT Jameel Clinic is housed in the MIT Schwarzman College of Computing. The mission of the Jameel Clinic is to "revolutionize the prevention, detection, and treatment of disease", and it describes itself as "the epicenter of AI and healthcare at MIT".
The MIT Jameel Clinic is known for using AI for the discovery of the antibiotics halicin and abaucin, and the development of early cancer detection platforms Mirai for breast cancer, and Sybil for lung cancer.